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EXECUTIVE SUMMARY 
I n  the past years, Pharma Sdn Bhd's revenue was depended on the toll 
manufacturing business as the major revenue contributor and over-the-counter 
(OTC) brands. However, the toll manufacturing contract expires in end of 1 999 
and the management decision was to phase out the toll manufacturing business 
by the end of 1 999 and venture into the ethical market. The ethical business 
was to start earning revenue in late 1 998, with investments breaking even in the 
year 2002. With the loss of income from tol l  manufacturing business, alternative 
revenue was needed to sustain  the company until the ethical range starts 
contributing positively in the year 2003. 
Pharma Sdn Bhd is now depended on the OTC business sector for revenue, 
particularly on the brand Freesia which is a 20 year old brand and currently the 
market leader in chewable Vitamin C for the adult market. The OTC business 
sector will be the major revenue contributor for the next five years ( 1 999 - 2003). 
The Vitamin C market is highly competitive as many players intensely compete 
in the open market and d irect sel l ing market. Furthermore, new entrants can 
easily enter the Malaysian market as currently there is no tax imposed on 
imported Vitamin C nor restrictions on the registration of products. Vitamin C is 
a vulnerable product to substitution and the chewable Vitamin C products are 
xi 
undifferentiated and standard ised allowing consumers to alternate between 
brands very easily. 
Pharma Sdn Bhd , as the market leader of the adult Vitamin C, is faced with a 
gradual loss of market share. This is reflected by sales performance of Freesia 
which was well below the budgeted sale in the year 1998. Another note for 
concern here ,  is that the sale of the existing product, have deteriorated whilst 
competitors had shown a growth of 5 % to 10% for their existing brands. 
To be able to sustain it's position as the market leader, the company needs to 
develop a d ifferentiated and sustainable strategy and apply common sense and 
experience to understand competitors' moves, if not, the company could loose 
vital market share in an overnight instance. 
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PART I : CASE TEXT 
1.0 QUARTERLY REVIEW PERFORMANCE MEETING 
The Managing Director, M r. Wee Chee Wah cal led the meeting to order and 
welcomed all members present. The meeting then proceeded : 
':As all of you are aware, the management has made a decision to phase out the 
toll manufacturing business by the end of 1999 as our toll manufacturing contract 
with Aztech, Keano Laboratories and Baytron will be ending this year and neither 
they nor we are interested in renewing the contract. The management has been 
looking at a more lucrative market, i.e. the ethical market (doctor's prescription), 
which is very promising in terms of returns. The research and development 
department has been developing the products for the ethical market since 
1996. The first launch was in the last quarter of last year. According to the 
management's plan, the ethical market was expected to start earning revenue 
late last year (1998) with investments breaking even in the year 2002. 
With the loss of income from the toll manufacturing business, revenue is needed 
to sustain the company until the ethical range starts contributing positively in the 
year 2003. ", he continued " We are now dependent on the over-the-counter 
(OTC) business sector, particularly on the brand Freesia, which is a 20 year old 
brand and currently the market leader in chewable Vitamin C for the adult 
market. 
The brand Freesia brings in almost 80% of the revenue for the OTe business 
sector with the rest coming from the other product lines. 
But, judging from the Freesia sales performance for the year 1997 and 1998 
(see appendix I and /I), you will note that the overall sales for the brand Freesia 
had increased by 55%, excluding the sales of two new products that were 
launched in 1998 i.e. , Freesia Sugar Free and Junior Multivitamins from RM 
737,000 in the year 1997 to RM 1,144,000 in the year 1998. However, the 
results were well below the budgeted sale of RM 2.14 million for the year 1998. 
Another note for concern here, is that the sale of Freesia (Orange) Vitamin C for 
adults has only increased marginally (14%) in comparison to the year 1997. 
We urgently need to do something about this as the revenue from the sale of 
Freesia is vital to keep the company going. The following budgeted sales has 
to be achieved by the brand Freesia (see appendix 11/ ), in order to obtain the 
needed revenue for the company to be able to sustain itself. Mr. Mahendra will 
be leading the task force set-up to achieve these targets and will be assisted by 
Dr. Koh and Ms. Teng. 
We also have to bear in mind that we are currently faced with a very competitive 
and volatile Vitamin C market. Mr. Mahendra will elaborate on this", said Mr. 
Wee. 
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'The vitamin C industry can be segmented by usage and value i.e, effervescents, 
time release and chewables. The chewables Vitamin C is not much 
differentiated, hence customer's switching cost is low. Therefore, sales volume 
seem to be determined by promotions, premium and discounts. In the bulk 
Vitamin market, hospitals purchase by tender and is very much price driven", 
said Mr. Mahendra Nathan,  the Marketing Manager. 
He continued, " The low switching cost is an incentive for new entrants. The 
recent example in Malaysia is the entry of Hebron and Organon from Australia 
and not to mention Citrex from a local supplier - Raza". 
"The manufacturing of chewable and coated Vitamin C except Effervescent is 
relatively easy. Plants that manufacture tablets can also manufacture Vitamin C, 
thus a lot smaller independent contract manufacturers are available for a 
competitor to choose from. Many direct selling companies have their own brands 
contract manufactured and enter the market easily. A firm only needs large 
manufacturing batches to keep costs low. As such, large volumes are pushed 
into the market creating price wars and eroding profits", explained Mr. 
Mahendra. 
Mr. Mahendra then said another  possible threat were multivitamins. He says, " 
today's consumers prefer a complete vitamin supplement rather than to pop 
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many pills each morning. Suppliers of multivitamins are the big guys with the 
necessary ammunition for promotion and branding. If, the Multivitamins prices 
drop to the level of Vitamin C prices, consumers will have a field day. If this 
happens it will certainly force us to revamp our entire business strategy". 
Mr. Kee interjected , 'The competitive base could also change if there are 
mergers (already happening in the "World pharmaceutical markets), as bigger 
players have more firepower. Eroding profits in the low end markets could also 
see the exit of some players, thus the remaining players have a bigger share". 
Mr. Mahendra continued, "Yet, the real threat is the lack of a good line extension 
for the brand Freesia. To start with, we launched the Freesia Junior Vitamin C in 
1997 and judging from the sales performance (refer to appendix I ) the sales has 
been encouraging. Last year, we produced a sugar free version of Vitamin C for 
adults and chewable Multivitamin for children. The sugar free version caters for 
the discerning health conscious adults and has received a good response. The 
launching of the three products has helped to further differentiate our product but 
it is not sufficient to sustain our position as a market leader in the long term". 
"If, we still wish to sustain our position as the market leader, it is vital that we 
develop a complete range of product line for Freesia and this has to be done 
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immediately. Presently, research and development is working on some new 
product lines and development is underway. It is imperative for Freesia to 
move into Effervescent and Time release markets with speed", emphasised Mr. 
Mahendra. 
"It is important that we are able to sustain the company with minimal support 
from the parent company as it reflects our capabilities. We should not forget that 
our pride, bonuses, salary and increments depends greatly on us meeting the 
stated target tl,e mphasised Mr. Wee. 
To stay on top of competition ,  u nless the company develops a differentiated and 
sustainable strategy and applies common sense and experience to understand 
the competitors' moves, one could lose vital market share in an overnight 
instance ( Porter, 1 985). This is the case in the explosion of generiC d rugs world-
wide. 
2.0 COMPANY BACKGROUND 
Pharma Sdn Bhd was a wholly owned subsidiary of BeB Berhad, a public l isted 
company in the Kuala Lumpur Stock Exchange (KLSE), under the Healthcare 
d ivision , see Appendix IV. 
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Pharma Sdn Bhd's principle activities were manufacturing and packaging of 
pharmaceuticals and over-the-counter (OTC) dosage forms, with over 30 years 
of experience. It also does contract repacking and marketing and sales of its own 
brands. Pharma Sdn Bhd has expertise in the preparation of tablets, capsules, 
l iquids and external preparations for the fol lowing medication and medical 
cond itions: 
• Vitamin C and Multivitamins I Minerals 
• Cough & Cold and Cough syrups 
• Tonic 
• Antacid I Antiflatulent 
• Analgesic 
• Antinflammatory 
• Antiasthmatic 
• Anti l ipid 
• Piles 
• Mouthwash 
• Liniment 
• Antiepileptic 
• Laxatives 
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I ts business activities are divided into three sectors, as exhibited in Appendix V. 
At the moment, its major revenue comes from toll manufacturing for Aztech, 
Keano Laboratories and Baytron .  However, the tol l  manufacturing business will 
cease operation by the end of 1999 and will be replaced by the eth ical business, 
which has started earning revenue in late 1 998. Under the OTC business sector, 
Pharma Sdn Bhd owns 3 brands - Freesia (Vitamin C), Boot's ( topical analgesic) 
and Berry's ( tonic ). 
Its mission statement is to provide Malaysians with medical and healthcare 
products and services of the highest quality. The objectives of Pharma Sdn Bhd 
are :-
• to provide customers with products and services that meet their evolving 
healthcare needs. 
• to achieve the highest standard in research and development through 
innovative d rug delivery and scientific research. 
• to produce and maintain the highest standard of qual ity in ethical products 
and services. 
• to maintain its position as market leader in the Vitamin C industry 
• to provide employees with rewarding and challenging careers. 
Pharma Sdn Bhd's organisation structure is shown in Appendix VI. 
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In th is paper, the d iscussion will be confined to the brand Freesia and the 
Vitamin C industry. 
3.0 ORAGANISATION'S CAPABILITIES 
3.1 FINANCIAL 
Pharma Sdn Bhd had a paid up  capital of RM 3.3 mil l ion and appendix VII and 
VIII shows the past three years,  1 996, 1 997 and 1 998, profit and loss accounts 
and balance sheet. 
"Even though, the company continues to grow at a healthy rate and it had 
recorded a net profit of RM 1.93 million last year, the cause for concern here is 
that as of the year 2000, we are faced with a the loss of income from toll 
manufacturing and the fixed income of RM 1.4 million from the manufacturing 
fees", said Ms. Linda Tay, the Finance Manager. She continued , " income is 
also generated from contract repa cking but, there has been a sharp drop in the 
year 1998 in comparison to the year 1997 and the same trend is expected to 
continue for the year 1999. However, it has been forecasted that the drop 
might only be marginal ". 
8 
" We are now dependent on the OTC business sector for income, to enable the 
company to sustain itself. Out of the three brands, about 80 % of the revenue 
earned comes from the brand Freesia. Freesia has a bigger customer base 
than the other two brands which are service items with a declining market. {{ 
"Even though, the ethical business has started earning income since last year, it 
is only expected to contribute positively in the year 2003. Till then, Freesia is 
expected to achieve a 20% annual sales growth for the year 1999 in comparison 
to the year 1998 (budgeted), 15% for the year 2000, 10% for the year 2001, 
2002 and 2003 respectively. 
3.2 MARKETING DEPARTMENT 
The marketing department was managed by M r. Mahendra who had two 
executives and one secretarial support. Sales was carried out by the d istributors 
but, the marketing of Freesia was controlled by Pharma Sdn Bhd . 
{{ To do a good marketing programme, an adequate advertising and promotion 
budget is needed", said Mr .  Mahendra .  Here, M r. Mahendra feels the company is 
reluctant to spend more on advertising and promotion as the management is 
more inclined in keeping the fixed cost/expenses down. Mr. Mahendra was 
u nhappy with this policy as he believes that "unless we are prepared to back the 
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product with a well planned advertising and promotion campaign, there is always 
a high possibility of failure. When a new product is launched its success or 
failure depends greatly on its marketing plan." 
Mr. Mahendra cited that in consumer marketing, the biggest share of voice 
transforms into a bigger share of market. He wished that the management would 
try to understand the importance of "above-the-line" advertising and promotion ( 
e.g .  television or cinema advertis ing) and give the marketing department its due 
recognition and not treat them as a stepchild . Mr. Mahendra also claimed that 
though, he and his team have excellent ideas, most of these ideas do not get 
implemented due to the lack of advertising and promotion funds. 
"However, the bigger threat, is the lack of a good line extension for the brand 
Freesia which will enable it to sustain itself into the 21st century. There are at 
least three competitors who already have a full umbrella range of products and 
this attracts customers as it tailors to more specific needs", said Mr. Mahendra. 
3.3 RESEARCH AND DEVELOPMENT DEPARTMENT 
Research and development department has all the facil ities to capitalise on new 
growth opportunities that would focus on innovative drug delivery 
systems/dosage form. 
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According to Dr Koh Lay Hong, from the registration and product testing team, 
the company has recently developed Sugar Free Vitamin C for adults and 
Vitamin C with Multivitamins for children under the brand Freesia Jun ior. He also 
said that the research and development department is currently working on a 
Time Release Vitamin C, Bio C,  Acid Free Time Release Vitamin C and 
Antioxidant + C for adu lts, under the Freesia brand . However, the department 
will not develop an effervescent form of Vitamin C due to high capital investment 
required for manufacturing effervescent. 
Many have g iven various ideas for new l ine extensions for Freesia but Dr. Koh 
cited that it wil l take some time before the product is endorsed and launched in 
the market. 
"More importantly the research and development department's focus i.e. 80%, is 
in developing innovative drugs for the ethical market and to do so an investment 
of RM 2 million has to been spent. From the year 1999 to 2001, a further 
investment of RM 3 to 5 million would be needed", said Dr. Koh. 
3.4 OPERATIONS I PRODUCTION DEPARTMENT 
'The production process requires a very high labour input as its production line is 
only partly automated as the machinery used in the production line is old, since 
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1963 ", said Ms. Mary Teng, the Works Manager. The reasons cited by Ms. Teng 
was that the machinery were in reasonable working condition and only needed 
regular servicing and 80% of the current labour force has been with the 
company for almost 20 years. 'The problem is that we have a high labour cost 
i. e. older workforce coupled with the limitation of the current machinery, it is 
difficult to increase productivity, hence higher cost of goods ", said Ms .  Teng. 
She continued by saying that the labour union were not receptive towards the 
management's ideas for increasing productivity. In spite of having numerous 
talks with union representatives, it was very d ifficult to motivate or convince 
them. Ms.  Teng feels that one of the reasons for the un ion's behaviour could be 
due to the stagnation in salary in the last two years. She said that management 
cannot indefinitely go on increasing the salary of workers. Therefore , the high 
cost of goods was also due to the high cost of labour. 
The amount to refurbish the entire production l ine would easily cost the company 
anywhere between RM 5 to 6 mil l ion . 'We need to carefully evaluate the 
investment as we feel that the returns should be financially viable. Furthermore, 
the research and development department also needs the money", explained Mr. 
Wee. 
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3.5 QUALITY ASSURANCE DEPARTMENT 
Accord ing to Mr. Solomon Banos , the Quality Assurance Manager, Pharma Sdn 
Bhd has a strict in-house qual ity assurance and quality control activities which is 
in compliance with GMP gu idel ines. He said that Pharma Sdn Bhd also compl ied 
with the yearly aud its by the Drug Control Authority of Malaysia , Aztech and 
Keano Laboratories International .  
M r. Solomon said that the types of qual ity assurance test carried out were : 
• Chemical analysis and microbial l imit test for products and raw materials 
• Stabil ity study for formulation change, packaging change and new products 
• Conduct testing for deionised water 
• Carry out microbial environmental evaluation 
• Carry out other activities l ike process validation ,  self-inspections, vendor 
audits, customer complaint evaluation , preventive maintenance for laboratory 
equ ipment and production machinery. 
"However, these strict quality assurance procedures have a tendency to increase 
the cost of manufactured goods. The marketing department is unhappy with this 
as they feel the quality assurance procedures are ve/y rigid. They have also 
suggested that we use a less stringent procedure, i.e. do away with some of the 
optional procedures." informed M r. Solomon.  Mr. Solomon stressed that the 
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